ADAR1 Capital Management
Overview
ADAR1 Capital Management, founded in October 2018 by Dr. Daniel Schneeberger, is an SEC-registered investment manager based in Austin, Texas. The firm specializes in public and private equity investments within the life sciences and biotechnology sectors. Dr. Schneeberger brings over 20 years of experience spanning scientific research, healthcare consulting, institutional investing, and executive leadership in the healthcare industry. He is supported by a team of professionals with deep medical and scientific expertise and a strong track record in biopharmaceutical investing. The firm's investment strategy emphasizes long-term growth and value creation, particularly in sectors with high potential for innovation and development. ADAR1 Capital Management has been actively involved in shareholder activism, notably engaging with Keros Therapeutics to influence its capital allocation and governance decisions. The firm has also made significant investments in companies such as Inhibikase Therapeutics Inc., reflecting its commitment to the healthcare sector. With assets under management totaling approximately $819.9 million as of March 31, 2025, ADAR1 Capital Management continues to focus on strategic investments that align with its expertise and investment philosophy.
Investment Focus
- Focus on life sciences and biotechnology sectors
- Preference for companies with innovative pipelines
- Interest in both public and private equity investments
- Emphasis on long-term growth and value creation
- Willingness to engage in shareholder activism to influence company strategy and governance
Portfolio Companies
Reach ADAR1 Capital Management directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about ADAR1 Capital Management
What sectors does ADAR1 Capital Management invest in?
ADAR1 Capital Management invests in Healthcare, Life Sciences, Pharmaceuticals and Biotechnology, and is based in Texas, United States. ADAR1 Capital Management is listed as a institutional investor in the ConnectSafely investor database.
What stage does ADAR1 Capital Management invest at?
ADAR1 Capital Management backs companies at Early Stage, Growth, Late Stage, Pre-IPO, Buyout and Turnaround, writing cheques of 1M - 50M.
Which regions does ADAR1 Capital Management invest in?
ADAR1 Capital Management invests across United States.
What companies has ADAR1 Capital Management invested in?
ADAR1 Capital Management's portfolio includes Keros Therapeutics, Roivant Sciences Ltd, Inhibikase Therapeutics Inc., Protagonist Therapeutics Inc., Zai Lab Ltd, Abivax SA, Prothena Corp PLC and Cytokinetics Inc.
Last updated · Source: ConnectSafely investor database
